anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
DORSAL GANGLIONS (DGS) are one of the most frequent problems of the wrist. They represent benign soft tissue tumors that frequently remain asymptomatic. Suggested causes include trauma to the scapholunate joint, degeneration of tissue lining a tendon or sheath near the joint, and synovial herniation in most cases, diagnosis is based on history and physical examination. Patients seek treatment when these ganglions become associated with pain, weakness, interference with activities, and an increase in size Other than observation, nonoperative treatment such as closed rupture, ganglion puncture, and needle aspiration is associated with relatively higher rates of recurrenceas high as 78%. Surgical treatment with either open or arthroscopic excision is therefore offered with a lower risk of recurrence. Whereas open excision has historically been the traditional method of surgical treatment, arthroscopic excision has been suggested as a potentially more favorable alternative. Proponents of wrist arthroscopy proclaim an advantage of decreased postoperative pain, earlier return of functions, and a smaller incision. Moreover, preliminary and subsequent studies have described arthroscopic DG excision as having equal or lower rates of recurrence. However, the results of arthroscopic versus open procedures have never been directly compared.
The dose of phenobarbital must be individualized with full knowledge of its particular characteristics. Factors of consideration are the patient’s age, weight, and condition.

: For sedation, the drug may be administered in single doses of 30 to 120 mg repeated at intervals; frequency will be determined by the patient’s response. It is generally considered that no more than 400 mg of phenobarbital should be administered during a 24-hour period. Sedation

: Daytime Sedation: 30 to 120 mg daily in 2 to 3 divided doses. Adults

: 100 to 200 mg Oral Hypnotic

–Clinical laboratory reference values should be used to determine the therapeutic anticonvulsant level of phenobarbital in the serum. To achieve the blood levels considered therapeutic in pediatric patients, higher per-kilogram dosages are generally necessary for phenobarbital and most other anticonvulsants. In pediatric patients and infants, phenobarbital at a loading dose of 15 to 20 mg/kg produces blood levels of about 20 mcg/mL shortly after administration. Anticonvulsant Use

Phenobarbital has been used in the treatment and prophylaxis of febrile seizures. However, it has not been established that prevention of febrile seizures influences the subsequent development of epilepsy.

Adults: 60 to 200 mg/day. Pediatric Patients: 3 to 6 mg/kg/day.   


–Dosage should be reduced in the elderly or debilitated because these patients may be more sensitive to barbiturates. Dosage should be reduced for patients with impaired renal function or hepatic disease. Special Patient Population
To compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 irritable bowel syndrome (IBS) patients, was selected. These controls were randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- (+/-2 years) and sex-matched (+/-5%) with the NCWS patients. The IBS controls had been receiving the same elimination diet as the NCWS patients and had not shown any clinical improvement; they belonged to the cohort of subjects the investigators had studied previously.
The principal objective is to use a cost-effectiveness study to assess the medical and economic impact of a new strategy for the screening and subsequent treatment of vaginal flora anomalies before the 20th week of gestation- molecular biology techniques (PCR for A. vaginae and G. vaginalis by point-of-care testing) will test self-collected vaginal samples in a population of pregnant women at low risk of preterm delivery. There are multiple secondary objectives, including assessment of the effect of the strategy on the following indicators- delivery before 26, 32, and 37 weeks. Methods-An open-label prospective randomized study will compare 2 groups with different management of their pregnancies. Pregnant women at low risk, regardless of any symptoms, will be randomized into 2 groups. The study will not include women at high risk of preterm delivery. Innovative strategy (group A)- these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique.
B-cell acute lymphoblastic leukemia is the most common type of leukemia and the prognosis of relapsed/refractory B-ALL is poor. Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy. CD19 CAR-T is the most commonly used engineered T cell in B-ALL. The treatment effect is significant and far more than traditional therapy in relapsed/refractory B-ALL. However, the remission time after CD19 CAR-T infusion is short.CD19-positive and CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients The cause of relapse after CAR-T infusion is minimal residual disease (MRD) which will induce CD19 negative relapse. CD20/CD22/CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment of CD19 negative relapse of B-ALL. Thus sequential treatment with CD20/CD22/CD10-CART after CD19-CART treatment in relapsed/refractory B-ALL will kill and eliminate CD19 negative B-ALL cells and prolong the remission time.
Solid menadione (2 - methyl - 1,4 - naphtho - quinone)-bisulphite compounds are prepared by mixing solid menadione with a solid non-toxic bisulphite in the presence of water in quantity less than enough to dissolve the materials present and drying the resultant addition compound by a heat treatment limited to a maximum temperature of substantially 60 DEG  C. The stability of the product is enhanced by the presence of excess bisulphite, preferably 1 1/4 -2\ba1/2 mols. per mol. of menadione.  The bisulphites of sodium, potassium, ammonium, di-n-butylamine, methylamine, trimethylamine, piperidine and diethylamine are the bisulphites specified in the examples.ALSO:Solid pharmaceutical preparations having anti-hemorrhagic activity similar to that of Vitamin K are prepared by mixing solid menadione (2 methyl-1, 4 naphthoquinone) with a solid non-toxic bisulphite in the presence of water in quantity less than enough to dissolve the materials present and drying the resultant addition compound by a heat treatment limited to a maximum temperature of substantially 60 DEG C.  The stability of the product is ensured by the use of excess bisulphite, preferably 1 1/4 -2\ba1/2 molecules per mol of menadione.  Inert materials such as lactose may also be incorporated.  The bisulphites of sodium, potassium, ammonium, di-n-butylamine, methylamine, trimethylamine, piperidine and diethylamine are the bisulphites specified in the examples.
The invention relates to a flurbiprofen axetil fat emulsion concentrate and a preparation method and use thereof, and belongs to the field of medicine and pharmacy. The flurbiprofen axetil fat emulsion concentrate overcomes the defects of complex traditional fat milk preparation process and poor product stability. The flurbiprofen axetil fat emulsion concentrate is simple in preparation process only needing simple physical mixing without homogenization process. The product can be sterilized through a 0.22 mum millipore filter film, can spontaneously emulsify during clinical use by dilution with normal saline or glucose solution and other water solutions and slight oscillation, under the optimal conditions, emulsified average particle size is about 0.2 mum, and fully shows injection fat milk properties. The flurbiprofen axetil fat emulsion concentrate product has good liquidity, and may not be hung on the wall, the appearance is single-phase, transparent and clear, clarity detection is acceptable, and after repeated freezing and thawing, preparation stratification phenomenon does not occur. The flurbiprofen axetil fat emulsion concentrate product is used for postoperative and cancer analgesia and other clinical application.
This study aims to determine the effects of transcutaneous spinal cord stimulation to increase blood pressure and use that device to increase exercise endurance time and heart rate recovery during arm cycle ergometry. In addition, the investigators will see if the stimulation helps regulate body temperature when in a cool environment. The study will consist of 7 visits, that will be between 3-4 hours in duration, separated by no less than 3 days. Visit 1 will consist of determining baseline autonomic function and screening visit. The participant will undergo a sit up set to determine hypotension and orthostatic hypotension and complete a couple surveys. Visits 2 and 3 will determine which site the stimulation parameters should be on the spine, either T7-T8 or T11-12. The site that increases seated systolic blood pressure will be used for the rest of the study. Visits 4 and 5 will consists of putting the electrode at the optimal spot on the spine and completing a submaximal arm ergometry exercise and the other visit will be a sham visit. Visits 6 and 7 will consist of assessing core temperature when in a cool environment with the stimulator on and off.
OBJECTIVES: Relatively few studies have investigated the effects of rehabilitation-based physical activity therapy as a treatment for older patients with advanced cancer. This study evaluated the effects of individualized precise and structured exercise interventions, prescribed by a rehabilitation physician, on fatigue, quality of life (QOL), and physical activity in older patients with advanced cancer.
METHODS: After admission to the rehabilitation department, older cancer patients were divided into groups receiving conventional symptomatic supportive therapy (SST) or physical activity therapy plus conventional symptomatic supportive therapy (PAT). The SST group was given symptomatic supportive treatment, exercised on their own, and were observed at home after their symptoms improved. The PAT group was required to implement physical exercise along with SST, involving 30 min of moderate-intensity exercise per day and 5 days per week, and were discharged after 4 weeks and instructed to continue to exercise outside the hospital. Cancer-related fatigue (CRF) at 4 and 8 weeks was the primary endpoint of the study, while the secondary endpoints included patients' QOL, physical activity, and exercise adherence rate.
RESULTS: Sixty-five patients were included; 37 (56.92%) chose to enter the PAT group, and 28 (43.08%) chose to enter the SST group. After 4 and 8 weeks of treatment, CRF relief and QOL improvement were significantly better in the PAT group than in the SST group (p < 0.05), whereas global health status did not differ between the two treatment groups (T1: p = 0.84; T2: p = 0.92). Mild physical activity significantly increased for the PAT group at T1 and T2 (T1: p = 0.03; T2: p = 0.005). At the T2 time point, the PAT group exhibited a higher level of participation in moderate-intensity physical activities as well as a higher total leisure activity score (p < 0.05). Thirty-three patients (94.29%) completed the PAT exercise program during hospitalization. Only four (12.12%) patients achieved moderate-intensity exercise, while the other 29 (87.88%) patients were able to continue exercising after their exercise intensity was decreased.
CONCLUSIONS: Implementation of precise and individualized exercise interventions, prescribed by the rehabilitation team, can lead to the reduction of CRF and improvement of QOL, and change in behavior related to physical activity.
A method for producing a stable polymerized hemoglobin blood-substitute from blood characterized in the use of a chromatographic column, is disclosed. The method of this invention includes mixing blood with an anticoagulant to form a blood solution, washing the red blood cells in the blood solution and then separating the washed red blood cells from the white blood cells. This method also includes disrupting the red blood cells to release hemoglobin and form a hemoglobin solution, which is then treated by high performance liquid chromatography to form a hemoglobin eluate. The hemoglobin eluate is then deoxygenated, contacted with a first reducing agent to form an oxidation-stabilized deoxygenated hemoglobin solution, and mixed with a cross-linking agent to form a polymerization reaction mixture, which is then polymerized. The polymerized hemoglobin solution is then diafiltered with a physiologic solution and with a reducing agent, whereby the polymerized hemoglobin solution is made physiologically acceptable, and whereby the reducing agent scavenges oxygen, to form a stable polymerized hemoglobin blood-substitute which is then packaged and stored in an atmosphere substantially free of oxygen. Compositions made by the methods are also disclosed, as are methods of therapeutically, or prophylactically, treating a vertebrate to increase tissue oxygenation, or prevent oxygen depletion, in tissue of the vertebrate.
Melanoma patients with brain metastases have a very poor outcome. Most patients with brain metastases will die from CNS related death. Radiation therapy is an effective treatment for patients with brain metastases for symptom palliation and survival benefit. Patients with multiple metastases are typically treated with whole brain radiation treatment (WBRT). For patients with a few metastases, stereotactic radiosurgery (SRS) alone can be used as an alternative. CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) antibody, Ipilimumab has shown efficacy in metastatic melanoma and unresectable melanoma. Treatment with high doses of radiation therapy would result in tumor cell death, releasing tumor debris and liberating potential tumor antigens. We hypothesize that combining radiation therapy with Ipilimumab will facilitate immune recognition of these novel tumor-specific antigens, yielding a synergistic effect. Further, the hypothesis of this study is that this combination could focus the immune system on tumor antigens and minimize the aberrant immune activation in normal tissues, consequently reducing the incidence of irAE's (immune related adverse effect). Combination of radiation treatment with Ipilimumab will likely result in better local control, decrease the risk of developing new brain metastases, and improved overall survival. However, the safety profile and toxicities of combining Ipilimumab with brain radiation treatment are unknown. The current phase I study will assess the safety profile of combining different doses of Ipilimumab with standard dose radiation treatment either with WBRT or SRS. The MTD (maximum tolerated dose) will be determined, as well as a recommended phase II trial dose of Ipilimumab.
Edible bird's nest (EBN) is a traditional food known for its nourishing and functional properties and is found to be involved in anti-oxidation, anti-aging, and anti-influenza mechanisms, immune regulation, and improving cardiovascular diseases, among others. However, the potential of EBN to improve glycolipid metabolism disorders in high-fat-diet induced obesity and the underlying mechanisms remain unexplored. We examined the effects of EBN on glycolipid metabolism in obese mice fed a high-fat diet. Male C57BL/6J mice were fed a high-fat diet for 8 weeks to establish an obesity model. The obese mice were selected and divided into six groups: two model control groups (normal and high-fat diets) and four intervention groups [Neu5Ac and low-, medium-, and high-dose EBN], with 12 mice in each group. After 10 weeks of continuous gavage intervention, only mice in the high-dose EBN intervention group had lower body weight and total fat content, especially visceral fat. Meanwhile, intervention with three doses of EBN reduced serum FBG, TC, LDL, Ox-LDL, IL-1β, IL-6, and TNF-α levels and increased serum HDL levels and energy expenditure. Using the high dosage as a paradigm, EBN intervention increased the sialic acid content in LDL, decreased TMAO in the liver, and increased GLP-1 levels in sera. EBN increased the colonic abundances of Akkermansia, Lactobacillus, and Desulfovibrio and reduced those of Lysinibacillus and Bacillus. The changes in the microbial community contribute to increasing colonic bile acids, reducing lipopolysaccharide synthesis to protect the intestinal barrier, and lowering inflammation levels. Changes were also observed in colonic transcripts and metabolites and liver gene transcripts and metabolites, which were mainly enriched in pathways of glycolipid metabolism, immune function amelioration, inflammatory signal mitigation, circadian rhythm, bile acid metabolism and insulin resistance. Therefore, EBN may enhance the gut microbiota and intestinal immunity, relieve chronic inflammation levels in serum, improve antioxidant capacity and circadian rhythm in the liver, promote bile acid metabolism, and decrease lipid absorption and lipid synthesis via the gut-liver axis. Consequently, this may reduce blood lipid and fat accumulation as well as improve islet function and reduce blood glucose levels.
PURPOSE:To prepare purified titled factor useful as an antitumor agent, by immobilizing one or more kinds of monoclonal antibodies prepared against human tumor necrosis factor in an affinity column, and passing a roughly refined liquid of said factor through the column. CONSTITUTION:A roughly refined liquid of human tumor necrosis factor (e.g. peripheral quadrimonocyte obtained by the cultivation in the presence of a substance having differentiation inducing capability, or the supernatant liquid of the cultivation medium of a cell strain established from the leukemia cell of a certain kind of myelogenous leukemia patient, etc.) is passed through an affinity column containing at least one kind of immobilized and supported monoclonal antibody produced against said factor (e.g. the antibody prepared by culturing a hybrid cell prepared by the cell fusion of a mouse lymphocyte B cell and a myeloma cell). The resultant purified human tumor necrosis factor is a protein having the following characteristics. Amino acid composition, shown in Table I ; molecular weight, 40,000-4,000 (by gel-filtration); isoelectric point, 6.0+ or -0.5; protein. EFFECT:It has excellent carcinostatic activity and low species specificity.
Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.
PURPOSE: To define the ophthalmic manifestations in KIF1A-associated neurologic disorder (KAND), a rare, progressive neurodegenerative disorder caused by pathogenic variants in the KIFA1 gene.
DESIGN: Cross-sectional study.
METHODS: Clinical ophthalmic examination and multimodal imaging were performed for 24 participants enrolled in the KIF1AOutcome measures, Assessments, Longitudinal And endpoints (KOALA) Study. Visual evoked potentials (VEPs) were performed on select participants.
RESULTS: The average central visual acuity in pediatric participants was 20/43 (logMAR 0.329, range 0.0-1.0) and 20/119 (logMAR 0.773, range 0.471-1.351) in adults. Ninety-five percent of participants examined had some degree of optic nerve atrophy detected by clinical examination and/or optical coherence tomography (OCT). Almost 40% had strabismus. Color vision, visual fields, and stereopsis were impaired in most participants who were able to participate in testing. VEP showed varying degrees of signal slowing and diffuseness.
CONCLUSIONS: Optic nerve atrophy is the primary ocular finding in individuals with KAND and is present at higher prevalence than previously reported. The degree of the atrophy is likely dependent on the severity of the pathogenic variant and possibly the age of the patient. Adults had worse vision on average than children, suggesting possible decline in vision with age. Strabismus in this cohort was common. VEPs showed findings consistent with optic neuropathy and visual dysfunction even in the absence of obvious structural changes on OCT. Families should be counseled regarding visual impairment in KAND patients, so as to obtain appropriate support and assistance to maximize safety, functionality, and learning.
Women and their spouses were provided couple-based family nursing based on dignity and respect, information sharing, participation and collaboration for 30-60 minutes with couple-based interviews for arm rehabilitation. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month.
PURPOSE:To obtain an antiviral polysaccharide suitable for treating viral hepatitis, etc. at a low cost, by fermenting gramineous vegetalbe fibers in an aqueous solution containing ammonia nitrogen, nitrate nitrogen, soluble phosphoric acid and soluble potassium. CONSTITUTION:Gramineous vegetable fibers, e.g. rice straw, are finely cut to chips of about 5-30mm. size, and mixed with a basic culture fluid consisting of water, ammonia nitrogen, nitrate nitrogen, soluble phosphoric acid and soluble potassium, put into a cultivation fermenter, closed and cultivated for about 120-240 days. Previously prepared protozoans, e.g. of the family Monadidae, may be added to the basic cultivating fermentation solution to shorten the cultivation period. After completing the cultivating fermentation, fibers are pressed and filtered to remove precipitates from the resultant filtrate by centrifugation. The filtrate is then ultrafiltered to remove metallic ions as impurities, and the resultant purified substance is sterilized to afford the aimed low-molecular weight polysaccharide.
Novel hydroxyethylidene-cyanoacetic acid anilides of formula Ia or their tautomeric form Ib are prepared by reacting a dialkylaminoethylidene-acetic acid anilide first at -70 to +50 DEG C with chlorosulphonyl or fluorosulphonyl isocyanate and subsequently at -30 to +25 DEG C with a tertiary amine. The reaction is carried out in an inert aprotic solvent. The reaction mixture obtained is rendered weakly alkaline and the dialkylaminoethylidene-cyanoacetic acid anilide formed is isolated from the lypophilic phase and is hydrolysed. The symbols in formulae Ia and Ib have the meaning given in the patent claim. The compounds of formula Ia and Ib as well as their physiologically tolerated salts exhibit powerful antiphlogistic and analgesic, as well as anthelminthic, antimycotic and fungicidal effects. <IMAGE>
PURPOSE:To provide the titled sensitizer useful for quick therapies e.g., removal or drilling of the dental caries by near-infrared laser beams, comprising respective coloring matters of green, blue, violet, intermediate color thereof and black in the hue circle for object color. CONSTITUTION:The objective sensitizer comprising respective coloring matters of green, blue, violet, intermediate color thereof and black in the hue circle for object color (e.g., respectively, Brilliant Green, Blue No.2, Methyl Violet and Sudan Black etc. each for use in edibles). This sensitizer is applied on the dental tissue such as carious dentin prior to or during laser beam irradiation to make near-infrared laser beams including semiconductor laser such as Na: YAG laser beams effectively absorb into the irradiated site, thus enhancing the therapeutic effect. Said sensitizer will also effective for the removal of the enamel. Furthermore, incorporation of this sensitizer into a laser- polymerizable resin will enhance its curing rate by ca. 20% compared to the case for a red coloring matter.